1366302-52-4 Usage
Uses
Used in Neurobiological Research:
1366302-52-4 is used as a research tool for investigating its potential therapeutic effects on neurological disorders, particularly Alzheimer’s disease. It is employed to understand the role of GSK3β inhibition in the treatment and management of neurodegenerative conditions.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1366302-52-4 is used as a lead compound in the development of new drugs targeting GSK3β. This is aimed at creating novel therapeutics for the treatment of various neurological disorders, with a focus on Alzheimer’s disease and other related conditions.
Used in Clinical Trials:
1366302-52-4 is utilized in clinical trials to assess its safety, efficacy, and potential side effects when used as a treatment for neurological disorders. These trials are essential for determining the viability of AZD1080 as a therapeutic agent and for guiding its future use in medical practice.
Check Digit Verification of cas no
The CAS Registry Mumber 1366302-52-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,6,3,0 and 2 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1366302-52:
(9*1)+(8*3)+(7*6)+(6*6)+(5*3)+(4*0)+(3*2)+(2*5)+(1*2)=144
144 % 10 = 4
So 1366302-52-4 is a valid CAS Registry Number.
1366302-52-4Relevant articles and documents
Synthesis of HBED–CC–tris(tert-butyl ester) using a solid phase and a microwave reactor
Jerzyk,Kludkiewicz,Pijarowska-Kruszyna,Jaron,Maurin,Sikora,Kordowski,Garnuszek
, (2021)
N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) belongs to the acyclic, bifunctional complexing compounds used mainly for radiolabeling with gallium-68 (68Ga). Due to the high stability of the 68Ga3+complex, HBED-CC is well known for its rapid and efficient labeling at ambient temperature and the high stability of the complexes in vivo. The HBED-CC chelator in combination with a PSMA (Prostate Specific Membrane Antigen) inhibitor and labeled with isotope of gallium is an important tool for diagnosing the stage of cancer in patients with prostate cancer. Many HBED-CC derivatives have been described in the literature, but one of the most commonly used is 3-(3-{[(2-{[5-(2-tert-butoxycarbonylethyl)-2-hydroxybenzyl]-tert-butoxycarbonylmethylamino}-ethyl)-tert-butoxy-carbonylmethylamino]-methyl}-4-hydroxyphenyl)propionic acid (HBED–CC–tris(tert-butyl ester)). This compound is very expensive and commercially limited. Therefore this work describes an innovative method of synthesis on solid phase using of a microwave reactor. Optimization of the reaction allowed to obtain HBED-CC-tris(tert-butyl ester) with high purity and yield.
